The spin stops here: inhibition of lipoprotein-associated phospholipase A2-- a promising target but a negative initial trial?
نویسندگان
چکیده
Current treatment strategies have resulted in significant reductions in morbidity and mortality associated with cardiovascular disease; however, significant residual risk remains. As an example, in the PROVE IT– TIMI 22 trial (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22), 22.4% of patients experienced an adverse event despite achieving a median LDL cholesterol concentration of 62 mg/dL (1.6 mmol/L) (1 ). These and similar findings have led to the search for novel therapeutic modalities. A logical place to start is control of inflammation. Darapladib (GlaxoSmithKline) is a novel oral therapeutic agent with potential antiinflammatory properties that inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is produced by macrophages and circulates bound to LDL. In experimental models, it appears to be central in the atherosclerotic process. Lp-PLA2 acts on oxidized phospholipids to produce free oxidized fatty acids and lysophosphatidylcholine, a proatherogenic inflammatory mediator that increases expression of adhesion molecules and cytokines, is a chemoattractant for macrophages, and induces vascular smooth muscle migration (2, 3 ). Immunohistochemical studies have shown that Lp-PLA2 is present in atherosclerotic lesions, and is particularly intense in “rupture-prone lipid laden” lesions with thin-cap fibroatheromas, (4 ). Unlike many other inflammatory mediators, Lp-PLA2 is not an acute-phase reactant (5 ); thus issues associated with acute-phase reactants are averted. For these reasons, Lp-PLA2 has emerged recently as an independent marker of cardiovascular risk and events. Although not all prospective studies have demonstrated an association between high plasma Lp-PLA2 concentrations and poor cardiovascular outcomes, the majority of studies reported are strongly positive. In a recent metaanalysis (6 ) including more than 20 000 patients from 14 epidemiologic studies, high Lp-PLA2 concentration was an independent risk factor for cardiovascular events. This is especially true in regard to the associations with stroke, which seem particularly strong (7, 8 ). These findings have persisted despite multiple iterations of the immunologic assay used with very different analytic characteristics and thus widely disparate absolute values (9 ).
منابع مشابه
The Effect of Eight Weeks of High-intensity Interval Training on Lipoprotein-associated Phospholipase A2 and Lipid Profile in a Male Rat Model of Type 2 Diabetes
Introduction: Type 2 diabetes (T2D) causes hyperglycemia, hyperinsulinemia, and dyslipidemia, which are all risk factors for atherosclerosis. Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been recognized as an indicator of atherosclerosis due to its role in vessel inflammation. This study aimed to investigate the effect of high-intensity interval training (HIIT) on serum levels of Lp-PL...
متن کاملLipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker
Within the last decade, a broad range of biomarkers associated with an increased risk for death and cardiovascular/cerebrovascular endpoints have been identified. Epide‐ miological studies clearly indicate that lipoprotein-associated phospholipase A2 (LpPLA2) has the potential to become clinically useful emerging biomarker in the true sense, linking plaque biology with cardiovascular/cerebrovas...
متن کاملPlatelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials
BACKGROUND We explored the theorized upregulation of platelet-activating factor (PAF)- mediated biologic responses following lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibition using human platelet aggregation studies in an in vitro experiment and in 2 clinical trials. METHODS AND RESULTS Full platelet aggregation concentration response curves were generated in vitro to several plate...
متن کاملLp-PLA2 Inhibition—The Atherosclerosis Panacea?
Based on the complex pathophysiology of atherosclerosis, a large number of biomarkers that relate to lipids, inflammation, immunity, thrombosis and hemostasis, have been investigated experimentally, in epidemiologic studies and in clinical trials. Interest focuses on their potential role to aid in risk stratification, as possible surrogate markers of atherosclerosis, and potential targets for t...
متن کاملTherapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a calcium-independent phospholipase A2 that circulates in plasma in association with lipoprotein particles, whereas in atherosclerotic plaques it is co-localized with macrophages. Lp-PLA2 generates two proinflammatory mediators, lysophosphatidylcholine and oxidized nonesterified fatty acids, which play a role in the development of atheroscler...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical chemistry
دوره 55 1 شماره
صفحات -
تاریخ انتشار 2009